Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2019 Dec 23;19(3):812–821. doi: 10.1158/1535-7163.MCT-19-0890

Table 1.

Summary of properties of RITs

RIT names IC50 (ng/ml) in
KLM 1
Half Max
Mesothelin
Binding
Half Life (min) AUC Rh
without PEG with PEG (%
Activity)
(μg/ml) Fast (α) Slow (β) (arbitrary unit,
x104)
(nm)
SS1P 0.19 n/a nt 19 n/a nt nt
LMB-12 0.22 n/a 0.022 ± 0.001 11 n/a 0.2 3.4
LMB-84 0.19 n/a nt nt n/a nt nt
LMB-249 0.22 ± 0.06 1.18 ± 0.03(18%) 0.027 ± 0.001 144 74400 5.9 7.1
LMB-203 0.29 ± 0.02 1.10 ± 0.19 (26%) 0.024 ± 0.004 59 51600 5.1 6.9
LMB-163 0.22 ± 0.03 1.13 ± 0.19 (19%) 0.029 ± 0.006 29 62284 4.3 5.6
LMB-179 0.21 ± 0.01 1.09 ± 0.13 (19%) 0.023 ± 0.002 38 26600 3.9 5.9
LMB-244 0.16 ± 0.03 0.25 ± 0.05 (64%) 0.013 ± 0.001 25 256 2.2 5.2

nt: not tested; n/a: not applicable

Bolded numbers refer to PEGylated RITs